SecBot SecBot

ABUS

Arbutus Biopharma Corp
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001447028 Biotech & Drug Discovery
$4.04 −0.05 (−1.22%)
Nov 16 4:00 PM ET · prev $4.09
Market cap
$627.0M
Small cap
Median target
🔒 Subscribers only
1 year
−11.0%
from $4.54 · Nov 17
30 days
−4.5%
from $4.23
52-week range
$3.66–5.22
−23% from high · low Nov 6
Avg volume 20D
2.51M
shares / day
Short interest
19.89M
≈13.0% of shares · −19.0%
Days to cover
9.1
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
2
Q3 2026 13F · 1 exit
Filing reports
21
analyzed by SecBot
SecBot read BULLISH 16 reports · 90 days
Balance 1 bearish · 6 bullish · 9 neutral oldest → newest, height = score
Avg score ·High conf. 10/16

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 22 added (2 new), 17 trimmed or exited.

  • Short sellersCOVERING

    Short interest −19.0% to 19.89M shares. 9.1 days to cover, ≈13.0% of shares.

  • TrendDOWNTREND

    9% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
1
exit
FundMoveSharesValue
BARCLAYS PLCTRIM2,548,572$12.2M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED1,947,718$9.3M
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED1,382,857$6.6M
Nuveen, LLCDOUBLED1,162,232$5.6M
CITIGROUP INCTRIM593,849$2.8M
Quadrature Capital LtdDOUBLED482,074$2.3M
AMERICAN CENTURY COMPANIES INCDOUBLED176,145$842.0K
VANGUARD ASSET MANAGEMENT, LtdADD120,351$575.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Nov 2025

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 14, 2025Chardan Capital
MAINTAIN
MAINTAINBuy
Aug 11, 2025Chardan Capital
MAINTAIN
MAINTAINBuy
Mar 28, 2025Chardan Capital
MAINTAIN
MAINTAINBuy
Jan 21, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 20, 2024Chardan Capital
MAINTAIN
MAINTAINBuy
Nov 18, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
Sawhney Roger
Director
Oct 1, 2026
TO ISSUER$85.7K
Oct 1, 2026
Androski Lindsay
President and CEO
Oct 1, 2026
TO ISSUER$123.3K
Oct 1, 2026
Beardsley Robert A
Director
Oct 1, 2026
TO ISSUER$89.7K
Oct 1, 2026
Nguyen Tuan
Chief Financial Officer
Oct 1, 2026
TO ISSUER$240.4K
Oct 1, 2026
Roivant Sciences Ltd.
Director
Oct 1, 2026
TO ISSUER$44.8M
Sep 18, 2026
Beardsley Robert A
Director
Sep 18, 2026
EXERCISE$168.1K
Sep 18, 2026
Beardsley Robert A
Director
Sep 18, 2026
EXERCISE$334.1K
Sep 18, 2026
Beardsley Robert A
Director
Sep 18, 2026
TAX W/H$502.2K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current QNoneNoneNo data$1.4M
Next Q-$0.03-$0.03–-$0.03-3.7%$1.4M
Current FY🔒 Fresh data, subscribers only
Next FY-$0.11-$0.11–-$0.11+10.5%$5.7M

Short side

FINRA· Oct 30, 2026
19,888,395
shares short
-19.0%
vs prior settlement
9.1
days to cover
≈13.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Earnings calendar
ABUS Q3 2026 Earnings Scheduled · 2026-11-11
Oct 22, 2026 Press
Arbutus Biopharma announced FDA removal of the clinical hold on its IND for AB-101, an oral PD-L1 inhibitor for…
Impact 7/10
Oct 1, 2026 Press
Arbutus Biopharma completed a modified Dutch auction tender offer, repurchasing 46 million shares for $230 million at…
Impact 7/10
Oct 1, 2026 Insider
Sawhney Roger disposed of 17,142 shares
Director @ $5.00 ($85.7K)
Oct 1, 2026 Insider
Androski Lindsay disposed of 24,655 shares
President and CEO @ $5.00 ($123.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

21 filings · 4 press releases · 10 bullish · 1 bearish · 2 mixed · 8 neutral
All ABUS filing & press-release reports (25)